Literature DB >> 15596140

Cloning and characterization of mouse disabled 2 interacting protein 2, a mouse orthologue of human NOSTRIN.

Young-Joon Choi1, Si-Young Cho, Hyung-Wook Kim, Jung-Ah Kim, Sung-Ho Bae, Sung-Soo Park.   

Abstract

The mouse disabled 2 interacting protein 2 (mDaIP2) had been obtained through yeast two hybrid system. It consists of 506 amino acids and its calculated molecular weight is 57.7 kDa. The protein contains N-terminal FCH domain and C-terminal SH3 domain. The SH3 domain interacts with the proline rich domain of mDab2 which had been identified to possess a transcriptional activation function. In RA-treated F9 teratocarcinoma cell, the mDaIP2 and mDab2 genes were differentially expressed in a RA-responsive manner and both were detected to localize in cytoplasm and nucleus. Homology search of all NCBI sequences indicated that the amino acid sequence of mDaIP2 shares 82% identity with human NOSTRIN which controls activity, trafficking, and targeting of nitric oxide synthase (eNos). The eNos was not detected in RA-treated F9 cell. These results suggest that mDaIP2 somehow functions in a different fashion from NOSTRIN in F9 cell differentiation and that its function may be concerted with that of mDab2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596140     DOI: 10.1016/j.bbrc.2004.11.079

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 and NOSTRIN.

Authors:  Kirstin Schilling; Nils Opitz; Anja Wiesenthal; Stefanie Oess; Ritva Tikkanen; Werner Müller-Esterl; Ann Icking
Journal:  Mol Biol Cell       Date:  2006-06-28       Impact factor: 4.138

2.  Nitric-oxide synthase trafficking inducer is a pleiotropic regulator of endothelial cell function and signaling.

Authors:  Shreeta Chakraborty; Rupasri Ain
Journal:  J Biol Chem       Date:  2017-02-24       Impact factor: 5.157

3.  Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression.

Authors:  Madhurima Paul; Tamal Kanti Gope; Priyanka Das; Rupasri Ain
Journal:  BMC Cancer       Date:  2022-05-31       Impact factor: 4.638

Review 4.  Life history of eNOS: partners and pathways.

Authors:  David M Dudzinski; Thomas Michel
Journal:  Cardiovasc Res       Date:  2007-04-03       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.